|
KMID : 0578320220450120869
|
|
Molecules and Cells
2022 Volume.45 No. 12 p.869 ~ p.876
|
|
|
Glyoxalase 1 as a Therapeutic Target in Cancer and Cancer Stem Cells
|
|
Kim Ji-Young
Jung Ji-Hye
Lee Seung-Joon
Han Seon-Sook
Hong Seok-Ho
|
|
|
Abstract
|
|
|
|
Methylglyoxal (MG) is a dicarbonyl compound formed in cells mainly by the spontaneous degradation of the triose phosphate intermediates of glycolysis. MG is a powerful precursor of advanced glycation end products, which lead to strong dicarbonyl and oxidative stress. Although divergent functions of MG have been observed depending on its concentration, MG is considered to be a potential anti-tumor factor due to its cytotoxic effects within the oncologic domain. MG detoxification is carried out by the glyoxalase system. Glyoxalase 1 (Glo1), the ubiquitous glutathione-dependent enzyme responsible for MG degradation, is considered to be a tumor promoting factor due to it catalyzing the removal of cytotoxic MG. Indeed, various cancer types exhibit increased expression and activity of Glo1 that closely correlate with tumor cell growth and metastasis. Furthermore, mounting evidence suggests that Glo1 contributes to cancer stem cell survival. In this review, we discuss the role of Glo1 in the malignant progression of cancer and its possible use as a promising therapeutic target for tumor therapy. We also summarize therapeutic outcomes of Glo1 inhibitors as prospective treatments for the prevention of cancer.
|
|
|
KEYWORD
|
|
|
cancer, cancer stem cell, glyoxalase 1, methylglyoxal
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|